Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.
Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. Nathan PJ, et al. Among authors: watson j, watson s. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. doi: 10.1017/S1461145712000752. Epub 2012 Aug 29. Int J Neuropsychopharmacol. 2013. PMID: 22932339 Free article. Clinical Trial.
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. Dawson LA, et al. Among authors: watson jm. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. doi: 10.1038/sj.npp.1301549. Epub 2007 Aug 29. Neuropsychopharmacology. 2008. PMID: 17728699
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW. Dawson LA, et al. Among authors: watson jm. Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30. Eur J Pharmacol. 2010. PMID: 19879867
Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ, Watson J, Reavill C. Langmead CJ, et al. Among authors: watson j. Pharmacol Ther. 2008 Feb;117(2):232-43. doi: 10.1016/j.pharmthera.2007.09.009. Epub 2007 Dec 20. Pharmacol Ther. 2008. PMID: 18082893 Review.
The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists.
Johnson DJ, Forbes IT, Watson SP, Garzya V, Stevenson GI, Walker GR, Mudhar HS, Flynn ST, Wyman PA, Smith PW, Murkitt GS, Lucas AJ, Mookherjee CR, Watson JM, Gartlon JE, Bradford AM, Brown F. Johnson DJ, et al. Among authors: watson sp, watson jm. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5434-8. doi: 10.1016/j.bmcl.2010.07.097. Epub 2010 Jul 30. Bioorg Med Chem Lett. 2010. PMID: 20709550
5,390 results